January 1, 2002
Anaheim, CA-The largest trial of cholesterol-lowering therapy ever conducted extends the current indications for statin therapy, reported Rory Collins, MD.  |
January 1, 2002
An agent developed specifically for the treatment of angina reduces the
incidence of major coronary events, reported Henry Dargie, MD, who presented
the results of a trial known as the Impact of Nicorandil in Angina (IONA).
It is believed to be the first large-scale trial to report on the effects
of a specific antianginal drug on clinical outcome. |
January 1, 2002
Ranolazine, the first in a new class of antianginal agents called the partial
fatty acid oxidation (pFOX) inhibitors, improves exercise performance and
reduces angina frequency in patients who still have symptoms despite treatment
with other antianginal medications, according to Bernard Chaitman, MD. He
reported the results of a Phase III study called the Combination Assessment
of Ranolazine in Stable Angina (CARISA). |
July 1, 2011
The selective beta3-adrenoceptor agonist mirabegron effectively improves symptoms of overactive bladder and is very safe and well tolderated, according to results of a phase 3 study.
|
July 1, 2011
The 5-alpha-reductase inhibitor dutasteride is associated with markedly lower BPH-related complication rates than the alpha-blocker tamsulosin, according to analysis of 2 large trials.
|
July 1, 2011
By:Michele B. Kaufman, PharmD, RPh
Comparative effectiveness research reviews are valuable resources for guiding medication use decisions, but they are underutilized, according to a recent presentation.
|
July 1, 2011
By:Michele B. Kaufman, PharmD, RPh
Some of the most prescribed blockbuster medications will lose market exclusivity in the next couple of years, according to a recent presentation.
|
June 1, 2011
By:Michele B. Kaufman, PharmD, RPh
The pipeline continues to decline from 4 to 5 years ago where smaller molecules led the way, according to a current state of the pharmaceutical pipeline presentation at the Academy of Managed Care Pharmacy's 23rd Annual Meeting and Showcase in Minneapolis.
|
June 1, 2011
By:Michele B. Kaufman, PharmD, RPh
Within the next 5 years, approximately $100 billion will be lost on previous blockbuster brands that will lose patent protection.
|
| 
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.